Celldex/$CLDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Ticker
$CLDX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
186
ISIN
US15117B2025
Website
Celldex Metrics
BasicAdvanced
$1.3B
-
-$2.70
1.14
-
Price and volume
Market cap
$1.3B
Beta
1.14
52-week high
$46.86
52-week low
$14.40
Average daily volume
1.1M
Financial strength
Current ratio
21.668
Quick ratio
21.029
Long term debt to equity
0.274
Total debt to equity
0.488
Profitability
EBITDA (TTM)
-213.94
Gross margin (TTM)
-2,340.84%
Net profit margin (TTM)
-2,366.07%
Operating margin (TTM)
-2,873.52%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-16.88%
Return on equity (TTM)
-23.20%
Valuation
Price to revenue (TTM)
177.892
Price to book
1.92
Price to tangible book (TTM)
2.04
Price to free cash flow (TTM)
-7.757
Free cash flow yield (TTM)
-12.89%
Free cash flow per share (TTM)
-261.57%
Growth
Revenue change (TTM)
24.49%
Earnings per share change (TTM)
-4.32%
3-year revenue growth (CAGR)
22.22%
10-year revenue growth (CAGR)
7.53%
3-year earnings per share growth (CAGR)
16.09%
10-year earnings per share growth (CAGR)
-18.02%
What the Analysts think about Celldex
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Bulls say / Bears say
Citigroup initiated coverage of Celldex Therapeutics with a Buy recommendation and a $70.00 price target, indicating strong confidence in the company's growth potential. (markets.businessinsider.com)
Celldex's barzolvolimab demonstrated a 95% complete response rate in a Phase 1b study for Chronic Inducible Urticaria, showcasing its potential efficacy in treating this condition. (investing.com)
Institutional investors like Renaissance Technologies LLC have recently increased their holdings in Celldex, reflecting growing confidence in the company's prospects. (etfdailynews.com)
Goldman Sachs initiated coverage of Celldex with a Neutral rating, citing concerns about the market opportunity for barzolvolimab and a lack of meaningful near-term catalysts. (seekingalpha.com)
The projected annual revenue for Celldex is $2 million, a decrease of 81.57%, indicating potential financial challenges ahead. (nasdaq.com)
Barzolvolimab's Phase 2 studies showed a drop in complete response rates from 95% in Phase 1b to 42-58%, raising concerns about its efficacy in larger trials. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Celldex Financial Performance
Revenues and expenses
Celldex Earnings Performance
Company profitability
Celldex News
AllArticlesVideos
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
GlobeNewsWire·2 weeks ago
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
GlobeNewsWire·3 weeks ago
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $1.3B as of June 30, 2025.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of June 30, 2025.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.